learn RU58841
a potent but unapproved and potentially problematic topical anti-androgen
Search
forLearn
5 / 801 resultslearn Lipodermal base
learn Fluridil
a topical anti-androgen with less systemic involvement
learn unspecified lectican proteoglycans (nourkrin)
learn ABN Complex
Research
5 / 329 results
research Distinct Transcriptional Profiles of the Female, Male, and Finasteride-Induced Feminized Male Anogenital Region in Rat Fetuses
Finasteride exposure affects gene expression and anogenital distance in male rat fetuses.
research Differences in anatomical area-specific wound healing in hidradenitis suppurativa/acne inversa after surgery
Wounds heal faster in the anogenital/inguinal area than in the axillary area after surgery for hidradenitis suppurativa.
research External genitalia abnormalities in male rats exposed in utero to finasteride, a 5α-reductase inhibitor
Finasteride exposure in pregnancy causes genital abnormalities in male rats.
research [Zinc deficiency dermatoses. Etiology, clinical aspects and treatment].
Zinc deficiency causes skin issues and hair loss, treatable with zinc supplements.
research Assessment of anogenital distance as a diagnostic tool in polycystic ovary syndrome
Measuring the distance from the anus to the clitoris may moderately help diagnose polycystic ovary syndrome, especially in certain cases.
Community Join
5 / 1000+ resultscommunity Proposed new pathogenesis model for androgenetic alopecia (AGA)
The conversation discusses a new model for understanding androgenetic alopecia (AGA), linking it to dietary and lifestyle factors similar to PCOS, and highlighting the role of DHT, vascular damage, and inflammation. Treatments mentioned include Minoxidil, finasteride, and RU58841.
community Get excited: The topical anti-androgen that's going to change everything
CB-03-01 is a topical anti-androgen with low absorption, offering potential as a side-effect-free alternative to Finasteride/Dutasteride for hair loss. It's in stage 2 clinical trials for acne and showing promise for male pattern baldness.
community AH-001 another topical AR degrader beside GT20029, completed Phase I
AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.
community Androgenic alopecia exclusively on the vertex of the scalp
A user experienced androgenic alopecia starting at the vertex without frontal hairline recession and is seeking information on this pattern. Another user noted that vertex or diffuse hair loss is common among men.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.